On Friday, the U.S. Food and Drug Administration (FDA) approved Takeda Pharmaceutical Co. Ltd.‘s (NYSE:TAK) MIMRYLO (rusfertide) for polycythemia vera, a type of blood cancer.
How MIMRYLO Combats Polycythemia Vera
Polycythemia vera forces the human body to overproduce red blood cells. This harmful overproduction dramatically increases blood thickness.
Increased viscosity places patients at high risk for life-threatening thrombotic events, which include severe complications like strokes, pulmonary embolisms, and deep vein thrombosis.
To prevent these severe health events, medical providers focus on keeping a patient’s hematocrit level strictly below 45%.
